ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A preliminary evaluation of efficacy and safety of Wharton's jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus

Liu Xuebin; Zheng Pei; Wang Xiaodong; Dai Guanghui; Cheng Hongbin; Zhang Zan; Hua Rongrong; Niu Xinxin; Shi Jing; An Yihua*
STEM CELL RESEARCH & THERAPY2014-4-23DOI: 10.1186/scrt446
12被引8阅读
引用收藏
分享

摘要

Introduction: Stem cell therapy has recently been introduced to treat patients with type 2 diabetes mellitus (T2DM). However, no data are available on the efficacy and safety of allogeneic Wharton's Jelly-derived mesenchymal stem cell (WJ-MSC) transplantation in patients with T2DM. Here we performed a non-placebo controlled prospective phase I/II study to determine efficacy and safety of WJ-MSC transplantation in T2DM. <br>Methods: Twenty-two patients with T2DM were enrolled and received WJ-MSC transplantation through one intravenous injection and one intrapancreatic endovascular injection (catheterization). They were followed up for 12 months after transplantation. The primary endpoints were changes in the levels of glycated hemoglobin and C-peptide and the secondary endpoints included insulin dosage, fasting blood glucose (FBG), post-meal blood glucose (PBG), inflammatory markers and T lymphocyte counts. <br>Results: WJ-MSC transplantation significantly decreased the levels of glucose and glycated hemoglobin, improved C-peptide levels and beta cell function, and reduced markers of systemic inflammation and T lymphocyte counts. No major WJ-MSC transplantation-related adverse events occurred, but data suggest a temporary decrease in levels of C-peptide and beta cell function at one month after treatment, possibly related to intrapancreatic endovascular injection. <br>Conclusions: Our data demonstrate that treatment with WJ-MSCs can improve metabolic control and beta cell function in patients with T2DM. The therapeutic mechanism may involve improvements in systemic inflammation and/or immunological regulation.

相关
加载中…
  • Stem Cell Transplantation in the Treatment of Type 1 Diabetes Mellitus: From Insulin Replacement to Beta-Cell Replacement
    Wan, Xin-Xing; Zhang, Dan-Yi; Khan, Md. Asaduzzaman; Zheng, Sheng-Yuan; Hu, Xi-Min; Zhang, Qi; Yang, Rong-Hua*; Xiong, Kun*Frontiers in Endocrinology, 2022, 13: 859638.被引 15
  • Therapeutic Effects of Stem Cells for the Treatment of Diabetes Mellitus
    Fei, Z. C.; Pei, R. J.; Du, X.; Pan, B.; Li, C. Q.; Cao, H. J.*INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 84: 226-234.
  • Immunological characteristics of human umbilical cord mesenchymal stem cells and the therapeutic effects of their transplantion on hyperglycemia in diabetic rats
    Wang Hongwu; Qiu Xiaoyan; Ni Ping; Qiu Xuerong; Lin Xiaobo; Wu Weizhao; Xie Lichun; Lin Limin; Min Juan; Lai Xiulan; Chen Yunbin; Ho Guyu; Ma Lian*International Journal of Molecular Medicine, 2014, 33(2): 263-270.被引 7
查看全部 →

发表信息

论文状态
公开发表
期刊
STEM CELL RESEARCH & THERAPY
发表日期
2014-04-23
卷期
第 5 卷
页码
57
DOI
10.1186/scrt446
语言
ENGLISH
期刊收录
SCIE
期刊等级
Q1
成果收录
SCI
资助标注
Department of Science and Technology, Guangdong Province, China [2011A081401003]; National Natural Science Foundation of China [81341043]; Beijing Municipal Natural Science Foundation [7122028]; General Hospital of Chinese People's Armed Police Forces Postdoctoral Science Foundation [WZ2011003]

作者

  • L

    Liu Xuebin (第一作者)

  • Z

    Zheng Pei

查看全部 10 位作者收起作者
  • W

    Wang Xiaodong

  • D

    Dai Guanghui

  • C

    Cheng Hongbin

  • Z

    Zhang Zan

  • H

    Hua Rongrong

  • N

    Niu Xinxin

  • S

    Shi Jing

  • A

    An Yihua (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417